期刊文献+

胶质瘤中CDK4和RASSF1A表达的相关性及意义 被引量:2

Correlation of CDK4 and RASSF1A expressions and their significance in glioma
原文传递
导出
摘要 目的研究细胞周期蛋白依赖性激酶4(CDK4)和RAS家族相关基因1A(RASSF1A)在脑胶质瘤中的表达情况及相关性。方法采用免疫组织化学SP法,检测70例脑胶质瘤患者、5例非正常死亡脑组织中CDK4和RASSF1A的表达,分析其相关性及与胶质瘤病理分级的关系。结果 CDK4和RASSF1A在不同级别胶质瘤中表达有统计学差异(P<0.05),CDK4与胶质瘤的病理分级呈正相关(rs=0.611,P<0.05),RASSF1A与胶质瘤的病理分级呈负相关(rs=-0.690,P<0.05);CDK4与RASSF1A在脑胶质瘤中的表达呈负相关(rs=-0.676,P<0.05)。结论 CDK4是胶质瘤的正性调节因子,RASSF1A是胶质瘤的负性调节因子,两者参与胶质瘤细胞的增殖和浸润。 Objective To investigate the expressions of cyclin-dependent kinase 4(CDK4) and RAS association domain family 1A(RASSF1A) and their correlation in human gliomas.MethodsImmunohistochemical SP stainning was used to examine the expressions of CDK4 and RASSF1A in 70 human glioma specimens and 5 normal human brain tissue specimens.The relationships among the expressions of CDK4 and RASSF1A in the pathological grade in human gliomas and clinical pathologic characters were analyzed.Results There were significant differences of CDK4 and RASSF1A expressions in different grades of gliomas(P〈0.05).CDK4 was positively correlated to the pathological grades of gliomas(rs=0.611,P〈0.05).A negatively correlation was found in the expression of RASSF1A and the grade of gliomas(rs=-0.690,P〈0.05).The expression of CDK4 was negatively correlated with RASSF1A(rs=-0.621,P〈0.05).Conclusion CDK4 is a possitive regulator and RASSF1A is a negative regulator for the development of glioma,both of which are involved in the proliferation and invasion of glioma.
出处 《江苏医药》 CAS CSCD 北大核心 2011年第12期1417-1419,共3页 Jiangsu Medical Journal
基金 江苏省高校自然科学研究项目(07KJD310172)
关键词 胶质瘤 周期蛋白依赖性激酶4 RAS家族相关基因1A Glioma Cyclin-dependent kinase 4 RAS association domain family 1A
  • 相关文献

参考文献5

  • 1蔡琼珍,姜汉国,唐慰萍,李飞虹.胃上皮异型增生并肠性化生PCNA、Cdk_4和Survivin的表达[J].宁夏医学杂志,2006,28(7):483-485. 被引量:1
  • 2Vos MD, Martinez A, Ellis CA, et al. The pro-apoptotic Ras effector Norel may serve as a Ras-regulated tumor suppressor in the lung[J]. J Biol Chem, 2003,278(24):21938- 21943.
  • 3Williams JG, Drugan JK, Yi GS, et al. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteinerich domain interactions [J]. J Biol Chem, 2000, 275 (29) : 22172-22179.
  • 4Yu MY, Tong JH, Chan PK, et al. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical eancers[J].Int J Cancer, 2003,105(2) : 204-209.
  • 5Chan MW,Chan LW, Tang NL, et al. Frequent hypermethylation of promoter region of RASSFIA in tumor tissues and voided urine of urinary bladder cancer patients[J]. Int J Cancer, 2003,104(5) : 611-616.

二级参考文献8

同被引文献16

  • 1王之敏,陶承.恶性脑胶质瘤分子靶向治疗研究进展[J].中国肿瘤,2006,15(3):158-162. 被引量:3
  • 2Woods M, Pant R, Mallya. SM. Cyclin D1 and cyclin D- dependent kinases enhance oral keratinoeyte proliferation but do not block keratinocyte differentiation [J]. Int J Oneol, 2010,37(6) :1471-1475.
  • 3Marretta RM,Ales F. Cancer ceil(s) cycle sequencing reveals universal mechanisms of apoptosis[J]. Mol Cell Biomech, 2010,7(4) :225-266.
  • 4Ming J,Jiang G, Zhang Q, et al. Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer [J]. Cancer Immunol Immunother, 2012, 61(1) :79-88.
  • 5Motiwale L, Naik N,Rao KV. Downregulation of cydin D1 is associated with decreased levels of p38 MAP kinases, Akt/ PKB and Pakl during chemopreventive effects of resveratrol in liver cancer cells[J]. Exp Toxicol Pathol, 2011,63 (1-2):167-173.
  • 6WdM, ZhuL,LiY,etak Knocking down cyclinDlb inhibits breast cancer cell growth and suppresses tumor development in a breast cancer model[J]. Caneer Sei,2011,102(8):1537- 1544.
  • 7Ayhan S, Isisag A, Saruc M, et al. The role of pRB, p16 and cyclin D1 in colonic cardnogenesis[J]. Hepatogastroenterology, 2010,57(98) :251-256.
  • 8Wu WK, Cho CH, Lee CW, et al. Dysregulation of cellular signaling in gastric cancer[J].Cancer Lett, 2010, 295 (2):144-153.
  • 9Tobin NP, Sims AH, Lundgren KL, et al. Cyclin D1, Idl and EMT in breast cancer[J]. BMC Cancer, 2011,11 : 417.
  • 10Musgrove EA,Caldon CE,Barraclough J,et al. Cyclin D as a therapeutic target in cancer[J]. Nat Rev Cancer, 2011, 11 (8) :558-572.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部